ArticleBMC ophthalmology2026
Longitudinal evaluation of optical coherence tomography parameters for detecting glaucoma progression across disease severities.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the longitudinal performance of multiple Optical Coherence Tomography (OCT) parameters in detecting glaucoma progression and compare their effectiveness with visual field (VF) parameters across disease stages.
methodsIn this longitudinal study, 59 glaucoma patients (mean follow-up: 8.51 years) underwent ≥ 5 serial OCT and VF assessments. Primary structural parameters included global RNFL, macular ganglion cell layer (mGCL) and macular retinal thickness (mRT). Progression was defined by significant thinning trends (OCT) or worsening VF indices: mean deviation or pattern standard deviation. Detection rates were compared overall and by disease severity and evaluated using survival analysis.
resultsOCT detected progression in significantly more eyes than VF (84.7% vs. 45.8%; p < 0.001). Among structural measures, mGCL demonstrated the highest progression detection rate (61.0%), followed by global RNFL (59.3%) and mRT (57.6%). In mild glaucoma, OCT significantly outperformed VF (87.5% vs. 50.0%; p < 0.001), with mGCL and inferior mRT demonstrating greater sensitivity at earlier stages (p < 0.05). In moderate-to-severe disease, OCT detection remained higher, though not statistically significant. Survival analysis demonstrated earlier and more frequent progression detection with OCT, with divergence increasing over time. By 10 years, structural parameters identified more progressing eyes than VF (57.0% vs. 38.6%). Combining structural and functional criteria did not significantly improve detection beyond OCT alone.
conclusionLong-term trend-based analysis demonstrates that structural OCT parameters detect glaucoma progression earlier and more frequently than VF testing, particularly in mild disease. These findings support prioritizing mGCL analysis alongside traditional RNFL imaging in routine glaucoma monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.